Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection.
Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection.
复制标题
低剂量白细胞介素-2 聚乙二醇衍生物在调节人类免疫缺陷病毒 1 型感染患者免疫反应中的功效。
DOI：
10.1093/infdis/167.2.291
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Cohn,Z
中科院分区：
文献类型：
--
作者：
Teppler,H;Kaplan,G;Smith,K;Cameron,P;Montana,A;Meyn,P;Cohn,Z
白细胞介素-2（IL-2）是细胞免疫中的关键细胞因子。人类免疫缺陷病毒1型（HIV-1）感染者由于CD 4 +T淋巴细胞数量低而缺乏IL-2。为了增强细胞免疫，通过皮内注射给予8名HIV-1感染男性10 μ g或180，000单位的低剂量重组人（rh）IL-2或9 μg或36，000单位的聚乙二醇（PEG）衍生物，持续30天。参与者没有机会性感染的证据，并同时接受齐多夫定。IL-2治疗是无毒的，并引起局部细胞反应类似经典的迟发型超敏反应（DTH）与局部干扰素-V的生产，即使在无能的患者。全身反应包括对回忆抗原的DTH反应增强，对有丝分裂原的体外增殖反应改善，以及NK细胞活性增强。外周白细胞表型和病毒滴度无变化。低剂量IL-2的长期研究是必要的，以确定免疫增强作用是否可以持续，如果它们与改善临床过程。
Interleukin-2 (IL-2) is a key cytokine in cellular immunity. Human immunodeficiency virus type 1 (HIV-1)-infected individuals lack IL-2 becauseoflow CD4+T lymphocyte numbers. In an attempt to enhance cellular immunity, low-dose recombinant human (rh) IL-2 at 10 ILg or 180,000 units or its polyethylene glycol (PEG) derivative at 9 µg or 36,000 units was given by intracutaneous injection to 8 HIV-1-infected men for 30 days. Participants had no evidence of opportunistic infection and received concurrent zidovudine. IL-2 treatment was nontoxic and elicited a local cellular response resembling classic delayed-type hypersensitivity (DTH) with local interferon-v production, even in anergic patients. Systemic responses included enhanced DTH responses to recall antigens, improved in vitro proliferative responses to mitogen, and enhanced NK cell activity. Peripheral leukocyte phenotype and virus titers were unchanged. Long-term studies of low-dose IL-2 are warranted to determine whether immunoenhancing effects can be sustained and if they are associated with improved clinical course.